PepGen Reports Positive Topline Results from Lowest-Dose (5 mg/kg) MAD Cohort in Phase 2 FREEDOM2 Study, Highlighting Safety, Splicing, and vHOT Outcomes PepGen has reported encouraging topline results from the lowest-dose cohort (5 mg/kg) in its ongoing Phase 2 FREEDOM2…
Eight Hospitals Earn National Recognition as Investments Enhance Care, Expand Services, and Strengthen Workforce One year after entering the Illinois healthcare landscape, Prime Healthcare and the Prime Healthcare Foundation have marked a significant milestone with more than $104 million invested…
DiaMedica Therapeutics Reports Full-Year 2025 Financial Results and Highlights Clinical Progress DiaMedica Therapeutics a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious conditions such as preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), has announced…
Organigram Shareholders Approve Sanity Group Acquisition and Key Resolutions at 2026 Annual Meeting Organigram Global has announced that its shareholders have overwhelmingly approved the company’s previously disclosed acquisition of Sanity Group GmbH, along with several other important resolutions, during its…
TruBridge Delays Reporting to Complete Year-End Audit, Sets New Earnings Release and Call Schedule TruBridge, Inc. has announced a revised schedule for the release of its financial results for the fourth quarter and full year ending December 31, 2025, along…
Emmaus Life Sciences Announces Full-Year 2025 Financial Results Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company focused on treatments for sickle cell disease, has reported its financial condition and operating results for the year ended December 31, 2025. The company’s…
Canopy Growth Corporation’s Apollo Cannabis Clinics Earn Top Honor in 2025 Toronto Star Readers’ Choice Awards SMITH FALLS, Ontario—Canopy Growth Corporation (“Canopy Growth” or “the Company”) has announced that its healthcare arm, Apollo Cannabis Clinics (“Apollo”), has been named Best…
Sensei Biotherapeutics Reports Full-Year 2025 Results, Advances PIKTOR Following Faeth Acquisition and $200 Million Financing Sensei Biotherapeutics, has reported its financial results for the full year ended December 31, 2025, while also providing a comprehensive corporate update highlighting major strategic…
Merck Reports Positive Phase 2 CADENCE Results for WINREVAIR in CpcPH-HFpEF, Supporting Advancement to Phase 3 Merck has announced encouraging results from its Phase 2 CADENCE clinical trial evaluating WINREVAIR™ (sotatercept-csrk) in adults diagnosed with combined post- and precapillary pulmonary…
Phase 3 data show significant reduction in LVOT gradient and a favorable safety profile, positioning Camzyos as a potential first targeted therapy for adolescents with oHCM Bristol Myers Squibb has reported encouraging results from the Phase 3 SCOUT-HCM trial evaluating…